WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.
|
|
- Erik Gaines
- 6 years ago
- Views:
Transcription
1 June 2017
2 WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. 3rd most populous country 50% of affected are children 30% will not see their 5th birthday 7.6 years to diagnose in US 80% OF RARE DISEASES ARE CAUSED BY MUTATIONS IN OUR GENOME.
3 RARE DISEASE COMPANY As one of the largest and most diversified genetic testing companies we are dedicated to transforming the worldwide science of genetic data into solutions and hope for patients and their families by answering two very important questions. 1. How to identify patients with a specific rare disease as early as possible? 2. What is the best treatment for these patients?
4 CENTOGENE Management CEO and CFO Prof. Arndt Rolfs, MD CEO, Founder Professor for Neurology, University of Rostock Consultant for international biotech and industrial companies Principal investigator of multiple international multicenter studies in the area of rare diseases > 220 peer-reviewed papers Richard Stoffelen CFO Certified Public Accountant Nearly 20 years of experience in Big 4 Accounting firm Head of Internal Audit at Holcim Group Services Experienced in IPOs and Bond issuances
5 CENTOGENE HIGHLIGHTS Established Global Footprint with Strong Historical Growth Growth by revenue (CAGR): > 40% Headquarters Germany Affiliations Delhi, Dubai, Vienna Cumulative Revenue > EUR 100 mill Outstanding historical growth In EUR million Receiving samples from over 110 countries
6 CENTOGENE HIGHLIGHTS Building the Definite Knowledge Base in Rare Disease ~ 300 employees Clients: > 16,000 Number of test in 2016 ~120,000 Academics employed: ~70% CentoMD Identified Individuals: ~120,000 Number of Genes in the Test Portfolio: >3,100
7 CENTOGENE s Business Model A self-amplifying value cycle building the Definite Knowledge Base in Rare Disease Knowledge Products Diagnostic s Pharma Collaborations Data, Information, Knowledge
8 Diagnostics The Foundation of Genetic Information and Entrance to Higher Value Added Solutions Knowledge Products Diagnostics Pharma Collaborations Samples Collection Sequencing Bioinformatics & Interpretation Medical Report Creation
9 CentoCard and CentoPortal Simple-to-use Logistics solution to Physicians and Patients SENDING SAMPLES AS POSTCARDS ORDER AND ACCESS TEST REPORTS AT ANY TIME FROM ANYWHERE
10 Pharmaceutical Collaborations High margin solutions monetized gained from Diagnostics services Knowledge Products Diagnostics Pharma Collaborations Data Knowledge CENTOGENE s is able to translate its Strengths into the needs of Pharmceutical companies and CROs by assisting them to: Patients screening and finding Clincial trails and marketable phases Biomarker development Trial design and planning Support clinical trial phases Companion Diagnostics Precision medicine supporting reimbusement Increase rare disease awareness from collaborational partnership and co-marketing efforts
11 EXAMPLES of BIOMARKER DEVELOPMENT at CENTOGENE
12 Knowledge Products Connecting knowledge between genotype and phenotype Knowledge Data Knowledge Products Diagnostics Pharma Collaborations Genetic Variants Clinical Symptoms Knowledge Data
13 CentoMD LARGEST MUTATION DATABASE FOF RARE DISEASES, FULLY CURATED, BASED ON CLINICAL AND GENETIC DATA CentoMD is our proof-of-concept for digital products that meet FDA s medical device regulation > 3,300 > 790 Mio > 4.0 Mio Centogene is a world-wide first mover in FDA-approved medical databases Genotype-Phenotype Phenotype-Genotype
14 CentoCloud offering Unique High Quality Bioinformatic Services Preparation Sequencing Processing Interpretation Communication Sequencing Billing Customer Customer Panel design & generation Sequencing Bioinformatic pipeline Technical & medical interpretation Creating medical report
15 CENTOGENE Accelerated growth by combination of new technologies
16 OUR BUSINESS MODEL IS SELF AMPLIFYING EVERY STEP OF THE WAY
17 THANK YOU
TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS
TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS THE DOORS ARE OPEN: FEEL FREE TO COME IN CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationCOPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES
COPE CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES FAQs This brochure addresses FAQ and is prepared solely for the German market. Local adjustments may be necessary. Please contact us if you require additional
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationResearch and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
More informationNew Frontiers in Personalized Medicine
New Frontiers in Personalized Medicine Oracle Open World Shanghai 2013 Neil de Crescenzo SVP and GM 1 Safe Harbor Statement The following is intended to outline our general product direction. It is intended
More informationMOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationFuture Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015
Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, 28-29 September 2015 (PhD) Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationUBS Global Life Sciences Conference
September 21, 2010 UBS Global Life Sciences Conference Tecan Group AG Thomas Bachmann, CEO September 21, 2010 / p2 / UBS Global Life Sciences Conference Introducing Tecan Provider of instruments and workflow-solutions
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationE2ES to Accelerate Next-Generation Genome Analysis in Clinical Research
www.hcltech.com E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research whitepaper April 2015 TABLE OF CONTENTS Introduction 3 Challenges associated with NGS data analysis 3 HCL s NGS Solution
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationVenture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013
Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program A FasterCures Webinar June 19, 2013 What is FasterCures? Founded in 2003, our mission is to save lives by saving
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationUBS Global Life Sciences Conference
September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO September 20, 2011 / p2 / UBS GLSC Contents Introducing Tecan Strategic Growth Drivers Financials H1 2011 &
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationGenomic Medicine in France
Genomic Medicine in France Catherine Nguyen, PhD Director ITMO GGB Genetic, Genomic & Bioinformatic Advancing Disease Modeling in Animal-Based research in Support of Precision Medecine: a Workshop ILAR
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationThe importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016
The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 Marianne Kock, Head of Global Regulatory Affairs & Managing Director, Ferring Pharmaceuticals
More informationORPHANET s Services for Researchers. Valérie THIBAUDEAU Database Manager Orphanet
ORPHANET s Services for Researchers Valérie THIBAUDEAU Database Manager Orphanet Services for Researchers Needs Access classifications, genes Identify experts Collaborate Quickly recruit volunteers Establish
More informationSAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014
Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationVoyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
More informationRare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationThe Belgian pharmaceutical industry strengthens its leading European position. Belgian pharma figures 2015, in a European perspective
The Belgian pharmaceutical industry strengthens its leading European position Belgian pharma figures 2015, in a European perspective INTRODUCTION In 2015, Belgium continued to reinforce its leading position
More informationComments on Use of Databases for Establishing the Clinical Relevance of Human Genetic Variants
Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 The American Society of Human Genetics 9650 Rockville Pike Bethesda, MD 20814 24 December
More informationLYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN
LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH EN www.lysarc.org THE LARGEST EUROPEAN ACADEMIC ORGANIZATION DEVOTED TO CLINICAL RESEARCH OPERATIONS IN THE LYMPHOMA FIELD Lymphoma is the 6th most
More informationThe 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
More informationSirtex Medical Limited
Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationAn Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case
Bench Lab CASE STUDY An Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case Authors: Matthew J. McGinniss 1, PhD FACMG, Executive Director, Molecular
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationProcess Mining HANA Platform and Startup at Celonis
Process Mining HANA Platform and Startup at Celonis Yves Colinet (Managing Partner Micropole) & Bastian Nominacher (Co-founder & Co-CEO Celonis) September, 2015 Celonis road to innovation with SAP October
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationBrazil Gastric Balloon Procedures Outlook to 2020
Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationEarly Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development
Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More informationTestimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association
Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory
More informationThe Clinical Research Regulatory Process
The Clinical Research Regulatory Process Understanding the Impact A CenterWatch-Complion Survey by Rick Arlow, Founder and CEO Complion Inc. Introduction The importance of data validity obtained from a
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationAdaptive Design for Medical Device Development
Adaptive Design for Medical Device Development A guide to accelerate clinical development and enhance portfolio value Executive Summary In May 2015, the FDA released a draft guidance document regarding
More informationThe Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing
The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing Grand Rounds: A Shared Forum of the NIH HCS Collaboratory and PCORnet June 30, 2017 Joseph S. Ross, MD, MHS Section of General
More informationParallel Scientific Advice- TLV s perspective. Wing Cheng DIA Euromeeting Vienna 26th March 2014
Parallel Scientific Advice- TLV s perspective Wing Cheng DIA Euromeeting Vienna 26th March 2014 Overview History: Pilot project TLV-MPA National advice process TLVs experience: EMA-HTA and EUnetHTA Comparison
More informationLA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES
LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES Francesca Pasinelli Direttore Generale 3 Congresso Nazionale SIFaCT Roma, 9 ottobre 2015 About Telethon Fondazione Telethon is
More informationHow can pharma outsourcing partners overcome the challenges of a rapidly changing industry?
How can pharma outsourcing partners overcome the challenges of a rapidly changing industry? ADAPTING TO CHANGE IN CONTRACT PHARMA How can pharma outsourcing partners overcome the challenges of a rapidly
More informationLife Sciences Practice
Life Sciences Practice The healthcare landscape has recently experienced considerable changes, including highly visible public demands for safer and improved healthcare systems. At the core of this is
More informationESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE
ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE An Economic Comparison of Programmatic and Transactional Development Models PETER SAUSEN,
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More informationCreating Shared Value: Redefining the Role of Business in Society
Creating Shared Value: Redefining the Role of Business in Society Mark Kramer Founder & Managing Director, FSG Senior Fellow, Harvard University prepared for: World Environment Center November 7, 2011
More informationHandbook. Precautions/warnings: For professional use only. To support clinical diagnosis. Not yet offered in the US. Page 1
Handbook Precautions/warnings: For professional use only. To support clinical diagnosis. Not yet offered in the US. Page 1 CentoMDx TM 1.1_Handbook_V1.1_March2018 Contents Introduction... 3 Intended use...
More informationBIOTECH IN FRANCE. key info in. points
BIOTECH IN FRANCE 10 key info in points 1 2 3 INSERM: EUROPE S #1 ACADEMIC BIOTECH RESEARCH INSTITUTE INSERM spearheads healthcare and medical research in France, filing more biotech patents with the European
More informationTOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
More informationTranslational Medicine From Discovery to Health
Translational Medicine From Discovery to Health Jamal A. Ibdah, MD, PhD Sr. Associate Dean & Director, MU Institute for Clinical and Translational Science Translational Medicine Translational Medicine
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationCHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS
Clinical Trial Supply 28 th 29 th October 2014 Princeton, NJ - USA CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS 1 Agenda The challenges associated with various
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationDepartment of Neurology. MRC Centre for Translational Research in Neuromuscular Diseases Second Scientific Advisory Board Review 21 st November 2011
Department of Neurology Robert C. Griggs, M.D. Professor of Neurology, Medicine, Pediatrics, Pathology & Laboratory Medicine and Center for Human Experimental Therapeutics MRC Centre for Translational
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationApollo Research and Innovations(ARI) Spearheading Healthcare Research and Innovations for Apollo Hospitals
Apollo Research Initiatives www.aherf.org (ARI) Spearheading Healthcare Research and Innovations for Apollo Hospitals About us The Apollo Mission A promise that redefined Healthcare Our mission is to bring
More informationTo Our Shareholders: Reaching Patients with PNH and ahus
To Our Shareholders: In 2014, Alexion continued to expand its commercial and clinical operations as we advanced our mission to develop and deliver life-transforming therapies for patients with severe and
More informationACCELERATING GENOMIC ANALYSIS ON THE CLOUD. Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia to analyze thousands of genomes
ACCELERATING GENOMIC ANALYSIS ON THE CLOUD Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia to analyze thousands of genomes Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia
More informationEnabling Precision Medicine: The Role of Genetics in Clinical Drug Development A Workshop
A Collaboration between the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health Enabling Precision Medicine: The Role of Genetics in Clinical Drug
More informationGenomic Data Is Going Google. Ask Bigger Biological Questions
Genomic Data Is Going Google Ask Bigger Biological Questions You know your research could have a significant scientific impact and answer questions that may redefine how a disease is diagnosed or treated.
More informationGrupo Fleury: history, market and strategic positioning, future. Mr. Carlos Marinelli Chief Executive Officer
Grupo Fleury: history, market and strategic positioning, future Mr. Carlos Marinelli Chief Executive Officer Grupo Fleury in numbers: purpose 90 years and reference healthcare company in Brazil 145 PSCs
More informationIntegrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA
Integrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA Scott W Binder MD Pritzker Professor of Clinical Pathology and Dermatology Senior Vice Chair Director, Pathology Clinical Services
More information4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015
4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015 VENUE: LINDNER HOTEL LANGE KIEVITSTRAAT 125 BE-2018 ANTWERP, BELGIUM 2 Join the 4 th one-day seminar to discuss
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationCollaborative Development Financing
Collaborative Development Financing 14 by Warren Nachlis and Wendy Brasunas The Growth of the Biotechnology Industry Pharmaceutical drug development is a risky and very expensive process. According to
More informationGreenwood Genetic Center
Greenwood Genetic Center: The Center for Human Genetics and The Partnership Campus A Growing Collaborative South Carolina Community Development Association Steve Skinner, M.D. Greenwood Genetic Center
More informationCFO meets M&A: Value creation in the digital age The Dbriefs Driving Enterprise Value series
CFO meets M&A: Value creation in the digital age The Dbriefs Driving Enterprise Value series Lukas Hoebarth, Principal, Deloitte Consulting LLP Nnamdi Lowrie, Principal, Deloitte Consulting LLP Carina
More informationNext Generation Sequencing (NGS) Market Size, Growth and Trends ( )
Next Generation Sequencing (NGS) Market Size, Growth and Trends (2014-2020) July, 2017 4 th edition Information contained in this market report is believed to be reliable at the time of publication. DeciBio
More informationCircle 5: Innovations in Dermatology and Clinical Trials
Circle 5: Innovations in Dermatology and Clinical Trials PRESENTED BY: MURAD ALAM, MD & PEARL E. GRIMES, MD New drugs, devices, cosmeceuticals Help companies disseminate their findings Access in residency
More informationOn Helix. 02 July Harren Jhoti President & CEO
On Helix 02 July 2014 Harren Jhoti President & CEO Astex Pharmaceuticals Global developer of small molecule drugs for unmet medical needs Expertise in oncology discovery & development World-class fragment-based
More informationMARCH 15-16, 2018 PARIS PALAIS BRONGNIART. An event of PROGRAM
MARCH 15-16, 2018 PARIS PALAIS BRONGNIART An event of PROGRAM DIAGNOSIS - March 15, 12:15-13:15 Precision diagnostic: genomics plans panorama French genomic national plan: PFM2025 England Genome: 100 000
More informationHelping unlock growth opportunities worldwide
Helping unlock growth opportunities worldwide A trusted partner for high-stakes decisions While scientific and technological advances fuel new business opportunities, the cost of bringing each new product
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationThe future of PMS in Healthcare IT: Announcing the cooperation with Epic. Stan Smits CEO Medical IT Philips Medical Systems
The future of PMS in Healthcare IT: Announcing the cooperation with Epic Stan Smits CEO Medical IT Philips Agenda Healthcare IT: business rationale Why Epic? Scope of the cooperation agreement Company
More informationQuintiles Transnational Corporation Big is Beautiful
Company Overview Quintiles Transnational Corporation Big is Beautiful Quintiles Transnational is the market leader in providing a full range of integrated product development and commercial development
More informationAkers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers
Akers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers 1 All statements pertaining to future financial and/or operating results,
More informationFrance Pressure Relief Devices Market Outlook to 2020
France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationPost-doctoral PharmD Fellowship Programs
Post-doctoral PharmD Fellowship Programs Table of Contents About Bioverativ Messages from Medical & Regulatory Our Pipeline Partnership with Northeastern University Global Medical Fellowship Global Regulatory
More informationQuantStudio Dx Real-Time PCR Instrument
QuantStudio Dx Real-Time PCR Instrument Behind every diagnosis, there is a promise You believe in molecular medicine. So do we. We are committed to providing you with comprehensive solutions that help
More information